Skip to main content
Erschienen in: International Journal of Clinical Oncology 6/2017

04.07.2017 | Original Article

A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer

verfasst von: Jianda Huang, Tongjie Gu, Jun Ying

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

A number of studies have investigated the clinical significance of bone turnover markers (BTMs) for the diagnosis of bone metastasis (BM) in lung cancer; however, they led to contradictory results. The aim of this meta-analysis was to investigate whether BTMs differ between lung cancer patients with and without BM.

Methods

Articles were identified by searching Medline, Embase, Web of Science and Scopus. The studies that were identified were pooled and the weighted mean difference (WMD) and its corresponding 95% confidence interval (CI) were calculated. Subgroup analyses and publication bias detection were also conducted.

Results

A final analysis of 1720 subjects (707 patients with BM and 1013 patients without BM) was performed from 16 cohort studies. From the pooled data in the meta-analysis, the total alkaline phosphatase (TALP) (104.35 U/l [95% CI 33.36−175.34]), bone-specific ALP (BALP) (13.24 μg/l [95% CI 8.50−17.98] or 6.84 U/l [95% CI 2.98−10.70]), C-terminal cross-linked telopeptide of type I collagen (ICTP) (5.07 μg/l [95% CI 3.58−6.56]) and N-terminal cross-linked telopeptide of type I collagen (NTX) (5.08 nM bone collagen equivalent/l [95% CI 2.82−7.33]) were significantly lower among BM patients than non-BM patients. Subgroup analyses detected that the serum level of tartrate-resistant acid phosphatase isoform 5b was significantly reduced in Caucasian patients with BM (−0.64 U/l [95% CI −1.02 to −0.25]), while increased in Asian patients with BM (2.69 U/l [95% CI 0.08−5.31]), compared to patients without BM.

Conclusions

The present meta-analysis suggested that serum measurement of TALP, BALP, ICTP and NTX might be helpful in detecting BM in lung cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fisseler-Eckhoff A (2010) Prognostic factors in histopathology of lung cancer. Front Radiat Ther Oncol 42:1–14PubMed Fisseler-Eckhoff A (2010) Prognostic factors in histopathology of lung cancer. Front Radiat Ther Oncol 42:1–14PubMed
2.
Zurück zum Zitat Yin JJ, Pollock CB, Kelly K (2005) Mechanisms of cancer metastasis to the bone. Cell Res 15:57–62CrossRefPubMed Yin JJ, Pollock CB, Kelly K (2005) Mechanisms of cancer metastasis to the bone. Cell Res 15:57–62CrossRefPubMed
4.
Zurück zum Zitat Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593CrossRefPubMed Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593CrossRefPubMed
5.
Zurück zum Zitat Lewis P, Griffin S, Marsden P et al (1994) Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 344:1265–1266CrossRefPubMed Lewis P, Griffin S, Marsden P et al (1994) Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 344:1265–1266CrossRefPubMed
6.
Zurück zum Zitat Ebert W, Muley T, Herb KP et al (2004) Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24:3193–3201PubMed Ebert W, Muley T, Herb KP et al (2004) Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24:3193–3201PubMed
7.
Zurück zum Zitat Gomez LN, Escalona S, Bandres B et al (2014) (18)F-fluorodeoxyglucose positron emission tomography/computed tomography accuracy in the staging of non-small cell lung cancer: review and cost-effectiveness. Radiol Res Pract 2014:135934 Gomez LN, Escalona S, Bandres B et al (2014) (18)F-fluorodeoxyglucose positron emission tomography/computed tomography accuracy in the staging of non-small cell lung cancer: review and cost-effectiveness. Radiol Res Pract 2014:135934
8.
Zurück zum Zitat Biver E (2012) Use of bone turnover markers in clinical practice. Curr Opin Endocrinol Diabetes Obes 19:468–473CrossRefPubMed Biver E (2012) Use of bone turnover markers in clinical practice. Curr Opin Endocrinol Diabetes Obes 19:468–473CrossRefPubMed
9.
Zurück zum Zitat Pecoraro V, Roli L, Germagnoli L et al (2015) The prognostic role of bone turnover markers in multiple myeloma patients: the impact of their assay. A systematic review and meta-analysis. Crit Rev Oncol Hematol 96:54–66CrossRefPubMed Pecoraro V, Roli L, Germagnoli L et al (2015) The prognostic role of bone turnover markers in multiple myeloma patients: the impact of their assay. A systematic review and meta-analysis. Crit Rev Oncol Hematol 96:54–66CrossRefPubMed
10.
Zurück zum Zitat Ferreira A, Alho I, Casimiro S et al (2015) Bone remodeling markers and bone metastases: from cancer research to clinical implications. Bonekey Rep 4:668CrossRefPubMedPubMedCentral Ferreira A, Alho I, Casimiro S et al (2015) Bone remodeling markers and bone metastases: from cancer research to clinical implications. Bonekey Rep 4:668CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Lumachi F, Santeufemia DA, Del CA et al (2013) Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer. Anticancer Res 33:2593–2596PubMed Lumachi F, Santeufemia DA, Del CA et al (2013) Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer. Anticancer Res 33:2593–2596PubMed
12.
Zurück zum Zitat Tang C, Liu Y, Qin H et al (2013) Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Clin Chim Acta 426:102–107CrossRefPubMed Tang C, Liu Y, Qin H et al (2013) Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Clin Chim Acta 426:102–107CrossRefPubMed
13.
Zurück zum Zitat Bayrak SB, Ceylan E, Serter M et al (2012) The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer. Int J Clin Oncol 17:112–118CrossRefPubMed Bayrak SB, Ceylan E, Serter M et al (2012) The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer. Int J Clin Oncol 17:112–118CrossRefPubMed
14.
Zurück zum Zitat Tamiya M, Suzuki H, Kobayashi M et al (2012) Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer. Med Oncol 29:215–218CrossRefPubMed Tamiya M, Suzuki H, Kobayashi M et al (2012) Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer. Med Oncol 29:215–218CrossRefPubMed
15.
Zurück zum Zitat Lumachi F, Marino F, Fanti G et al (2011) Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results. Anticancer Res 31:3879–3881PubMed Lumachi F, Marino F, Fanti G et al (2011) Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results. Anticancer Res 31:3879–3881PubMed
16.
Zurück zum Zitat Yao NS, Wu YY, Janckila AJ et al (2011) Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients. Clin Chim Acta 412:181–185CrossRefPubMed Yao NS, Wu YY, Janckila AJ et al (2011) Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients. Clin Chim Acta 412:181–185CrossRefPubMed
17.
Zurück zum Zitat Terpos E, Kiagia M, Karapanagiotou EM et al (2009) The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 29:1651–1657PubMed Terpos E, Kiagia M, Karapanagiotou EM et al (2009) The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 29:1651–1657PubMed
18.
Zurück zum Zitat Min JW, Um SW, Yim JJ et al (2009) The role of whole-body FDG PET/CT, Tc 99 m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci 24:275–280CrossRefPubMedPubMedCentral Min JW, Um SW, Yim JJ et al (2009) The role of whole-body FDG PET/CT, Tc 99 m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci 24:275–280CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Dane F, Turk HM, Sevinc A et al (2008) Markers of bone turnover in patients with lung cancer. J Natl Med Assoc 100:425–428CrossRefPubMed Dane F, Turk HM, Sevinc A et al (2008) Markers of bone turnover in patients with lung cancer. J Natl Med Assoc 100:425–428CrossRefPubMed
20.
Zurück zum Zitat Chung JH, Park MS, Kim YS et al (2005) Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J 46:388–393CrossRefPubMedPubMedCentral Chung JH, Park MS, Kim YS et al (2005) Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J 46:388–393CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Yokoyama T, Yamamoto M, Shima K et al (2005) Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer. Respirology 10:300–304CrossRefPubMed Yokoyama T, Yamamoto M, Shima K et al (2005) Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer. Respirology 10:300–304CrossRefPubMed
22.
Zurück zum Zitat Alatas F, Alatas O, Metintas M et al (2002) Usefulness of bone markers for detection of bone metastases in lung cancer patients. Clin Biochem 35:293–296CrossRefPubMed Alatas F, Alatas O, Metintas M et al (2002) Usefulness of bone markers for detection of bone metastases in lung cancer patients. Clin Biochem 35:293–296CrossRefPubMed
23.
Zurück zum Zitat Izumi M, Nakanishi Y, Takayama K et al (2001) Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer 91:1487–1493CrossRefPubMed Izumi M, Nakanishi Y, Takayama K et al (2001) Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer 91:1487–1493CrossRefPubMed
24.
Zurück zum Zitat Horiguchi T, Tachikawa S, Kondo R et al (2000) Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer. Jpn J Clin Oncol 30:174–179CrossRefPubMed Horiguchi T, Tachikawa S, Kondo R et al (2000) Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer. Jpn J Clin Oncol 30:174–179CrossRefPubMed
25.
Zurück zum Zitat Aruga A, Koizumi M, Hotta R et al (1997) Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76:760–764CrossRefPubMedPubMedCentral Aruga A, Koizumi M, Hotta R et al (1997) Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76:760–764CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRefPubMedPubMedCentral Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed
29.
Zurück zum Zitat DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed
30.
Zurück zum Zitat Coleman R, Brown J, Terpos E et al (2008) Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34:629–639CrossRefPubMedPubMedCentral Coleman R, Brown J, Terpos E et al (2008) Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34:629–639CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Lipton A, Costa L, Ali SM et al (2001) Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27:181–185CrossRefPubMed Lipton A, Costa L, Ali SM et al (2001) Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27:181–185CrossRefPubMed
32.
Zurück zum Zitat Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69CrossRefPubMed Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69CrossRefPubMed
33.
Zurück zum Zitat Ali SM, Demers LM, Leitzel K et al (2004) Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15:455–459CrossRefPubMed Ali SM, Demers LM, Leitzel K et al (2004) Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15:455–459CrossRefPubMed
34.
Zurück zum Zitat Kaira R, Murakami H, Kaira K et al (2010) N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases. Int J Clin Oncol 15:484–488CrossRefPubMed Kaira R, Murakami H, Kaira K et al (2010) N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases. Int J Clin Oncol 15:484–488CrossRefPubMed
35.
Zurück zum Zitat Magnusson P, Larsson L, Magnusson M et al (1999) Isoforms of bone alkaline phosphatase: characterization and origin in human trabecular and cortical bone. J Bone Miner Res 14:1926–1933CrossRefPubMed Magnusson P, Larsson L, Magnusson M et al (1999) Isoforms of bone alkaline phosphatase: characterization and origin in human trabecular and cortical bone. J Bone Miner Res 14:1926–1933CrossRefPubMed
36.
Zurück zum Zitat Seibel MJ (2005) Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2(504–517):1–533 Seibel MJ (2005) Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2(504–517):1–533
37.
Zurück zum Zitat Janckila AJ, Takahashi K, Sun SZ et al (2001) Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 47:74–80PubMed Janckila AJ, Takahashi K, Sun SZ et al (2001) Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 47:74–80PubMed
38.
Zurück zum Zitat Wu YY, Janckila AJ, Ku CH et al (2010) Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis. BMC Cancer 10:158CrossRefPubMedPubMedCentral Wu YY, Janckila AJ, Ku CH et al (2010) Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis. BMC Cancer 10:158CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Wada N, Ishii S, Ikeda T et al (1999) Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer. Anticancer Res 19:4515–4521PubMed Wada N, Ishii S, Ikeda T et al (1999) Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer. Anticancer Res 19:4515–4521PubMed
40.
Zurück zum Zitat Mountzios G, Ramfidis V, Terpos E et al (2011) Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Clin Lung Cancer 12:341–349CrossRefPubMed Mountzios G, Ramfidis V, Terpos E et al (2011) Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Clin Lung Cancer 12:341–349CrossRefPubMed
Metadaten
Titel
A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer
verfasst von
Jianda Huang
Tongjie Gu
Jun Ying
Publikationsdatum
04.07.2017
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 6/2017
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1159-1

Weitere Artikel der Ausgabe 6/2017

International Journal of Clinical Oncology 6/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.